{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:46:56Z","timestamp":1769636816075,"version":"3.49.0"},"reference-count":0,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neonatology"],"published-print":{"date-parts":[[1999]]},"abstract":"<jats:p>&lt;i&gt;Aim:&lt;\/i&gt; To study the effect of doxapram on the frequency of apnoea, bradycardia and hypoxaemia. &lt;i&gt;Methods:&lt;\/i&gt; Fifteen infants, median gestational age at birth 27 weeks (range 24\u201330), age at study 27 days (12\u201360), with \u22656 episodes of bradycardia or hypoxaemia\/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0.5\u20132 mg\/kg\/h) or orally (2\u20138 mg\/kg every 2 h). Six-hour recordings of pulse oximeter saturation (S&lt;sub&gt;P&lt;\/sub&gt;O&lt;sub&gt;2&lt;\/sub&gt;), pulse waveforms, ECG, breathing movements and nasal airflow were performed immediately before as well as 1, 3 and 6 days after onset of treatment. Recordings were analysed for apnoea (\u22654 s), bradycardia (heart rate &lt; 2\/3 of baseline) and hypoxaemia (S&lt;sub&gt;P&lt;\/sub&gt;O&lt;sub&gt;2&lt;\/sub&gt; \u226480%). &lt;i&gt;Results:&lt;\/i&gt; There was no difference between enteral and intravenous administration; results are therefore presented for the total group. Doxapram resulted in a significant decrease in the frequency of apnoea [22 (11\u201327) vs. 14 (7\u201323)\/h, p &lt; 0.01], bradycardia [3 (0\u20137) vs. 1 (0\u20133)\/h, p &lt; 0.01] and hypoxaemia [8 (0\u201318) vs. 2 (0\u2013 17)\/h, p &lt; 0.01] already after 1 day of treatment, which was sustained throughout the 6-day study period. Side effects included an increase in the proportion of time spent awake [5 (0\u201324) vs. 12% (3\u201328), p &lt; 0.01] and in gastric residuals [0% of feeding volume (0\u20135) vs. 4% (0\u201319), p &lt; 0.05]. Enteral was switched to intravenous doxapram in 3 of 9 infants because of gastrointestinal side effects. &lt;i&gt;Conclusion:&lt;\/i&gt; Doxapram substantially reduced the frequency of apnoea, bradycardia and hypoxaemia in these patients with caffeine-resistant apnoea of prematurity. Enteral administration, however, was not tolerated in a significant proportion (33%) of infants.<\/jats:p>","DOI":"10.1159\/000014160","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T15:43:24Z","timestamp":1050421404000},"page":"207-213","source":"Crossref","is-referenced-by-count":45,"title":["Effect of Doxapram on Episodes of Apnoea, Bradycardia and Hypoxaemia in Preterm Infants"],"prefix":"10.1159","volume":"76","author":[{"given":"Christian F.","family":"Poets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Darraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Bohnhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[1999,9,3]]},"container-title":["Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/14160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/14160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:08:13Z","timestamp":1745471293000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000014160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000014160","archive":["Portico"],"relation":{},"ISSN":["1661-7800","1661-7819"],"issn-type":[{"value":"1661-7800","type":"print"},{"value":"1661-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999]]}}}